

Funder	Project Title	Funding	Institution
Brain & Behavior Research Foundation	Mechanism-based Treatment Targets and Biomarkers for Genetically Defined Mental Illnesses	\$25,000	Cincinnati Children's Hospital Medical Center
Brain & Behavior Research Foundation	Modulation of the Oxytocin System in a Mouse Model of Autism Spectrum Disorder (ASD)	\$16,079	University of the Basque Country
Department of Defense - Army	Early Treatment of Language Impairment in Young Children with Autism Spectrum Disorder with Leucovorin Calcium	\$1,129,610	Children's Hospital, Phoenix
Department of Defense - Army	Treating Gastrointestinal and Autism Symptoms in Adults with Autism Using Microbiota Transfer Therapy (MTT)	\$0	Arizona State University
Department of Defense - Army	Biologic Mechanisms and Efficacy of Cerebellar Transcranial Direct Current Stimulation in ASD	\$713,869	Texas, University of, Southwestern Medical Center at Dallas
Department of Defense - Army	Development of Novel Drugs Targeting Serotonin Receptors to Treat Motor, Social, Cognitive, and Sensory Domains of Autism Spectrum Disorder Using Mouse Models	\$0	Mercer University
Department of Defense - Army	Sulforaphane Treatment of Children with Autism Spectrum Disorder (ASD)	\$0	University of Massachusetts Medical School
Department of Defense - Army	Development of Novel Drugs Targeting Serotonin Receptors to Treat Motor, Social, Cognitive, and Sensory Domains of Autism Spectrum Disorder Using Mouse Models	\$0	Northeastern University
Department of Defense - Army	Trial of Propranolol in Children and Youth with ASD and Predictors of Response	\$0	University of Missouri
Department of Defense - Army	Cannabidiol (CBD) Versus Placebo in Children with Autism Spectrum Disorder (ASD)	\$0	Albert Einstein College of Medicine
Autism Research Institute	To study the effect of zinc therapy on ERK levels in individuals with autism	\$7,485	Hartwick College
Autism Science Foundation	Screening for new autism treatments using cells in a dish	\$0	University of California, San Diego
Autism Speaks	Response Heterogeneity to GI Treatment, Autism Symptom and Improved Oxidative Stress	\$148,976	Children's Hospital of Los Angeles
Autism Speaks	Nicotinic cholinergic modulation as a novel treatment strategy for aggression associated with autism	\$63,700	Yale University
Autism Speaks	PACT contract	\$350,250	Boston Children's Hospital
Autism Speaks	Pilot study of Minocycline	\$23,000	University of Missouri at Columbia
Autism Speaks	Autism Treatment Network - Pilot study of Minocycline	\$42,000	Cincinnati Children's Hospital Medical Center
Autism Speaks	Double-blind, placebo-controlled target engagement study of minocycline in autism spectrum disorder	\$36,000	University of Pittsburgh
Health Resources and Services Administration	A Controlled Trial of Sertraline in Young Children with ASD	\$0	University of California, Davis
Health Resources and Services Administration	Autism Intervention Research Network on Physical Health (AIR-P network)	\$2,991,590	Massachusetts General Hospital
Health Resources and Services Administration	Investigation of Teacher-Mediated Toilet Training Using a Manualized Moisture Alarm Intervention	\$0	University of Rochester Medical Center

Funder	Project Title	Funding	Institution
National Institutes of Health	Preventing Epilepsy Using Vigabatrin in Infants with Tuberous Sclerosis Complex	\$1,496,413	University of Alabama at Birmingham
National Institutes of Health	A High-dose Folinic Acid Treatment for Core and Associated Symptoms of Autism	\$558,921	Phoenix Children'S Hospital
National Institutes of Health	Intranasal Vasopressin Treatment in Children with Autism	\$604,364	Stanford University
National Institutes of Health	Proof of Mechanism Study for the Treatment of Social Anhedonia in ASD	\$286,244	University of California Los Angeles
National Institutes of Health	Novel Therapy for Fragile X Syndrome	\$317,514	Epigen Biosciences, Inc.
National Institutes of Health	Specifying and Treating the Anxiety Phenotype in Autism Spectrum Disorder	\$534,077	University of California at Davis
National Institutes of Health	Transcriptional Signature Profiling of IGF1-Treated Neural Cells from Idiopathic Autistic Patients	\$96,200	Salk Institute For Biological Studies
National Institutes of Health	3/5-The Autism Biomarkers Consortium for Clinical Trials	\$413,293	Yale University
National Institutes of Health	4/5-The Autism Biomarkers Consortium for Clinical Trials	\$389,926	Yale University
National Institutes of Health	1/5-The Autism Biomarkers Consortium for Clinical Trials	\$417,095	Yale University
National Institutes of Health	Data Acquisition and Analysis Core	\$2,864,255	Yale University
National Institutes of Health	2/5-The Autism Biomarkers Consortium for Clinical Trials	\$427,653	Yale University
National Institutes of Health	5/5-The Autism Biomarkers Consortium for Clinical Trials	\$426,029	Yale University
National Institutes of Health	Administrative Core	\$923,289	Yale University
National Institutes of Health	Data Coordinating Core	\$928,131	Yale University
National Institutes of Health	Regulation of 22q11 Genes in Embryonic and Adult Forebrain	\$445,484	George Washington University
National Institutes of Health	Preclinical Imaging of Adolescent Cannabidiol on Brain Structure and Functional Connectivity	\$76,250	University of Florida
National Institutes of Health	Integrated Treatments for Core Deficits in Autism Spectrum Disorder	\$146,796	Rush University Medical Center
National Institutes of Health	A Drug-Screening Platform for Autism Spectrum Disorders Using Human Neurons and Astrocytes	\$127,680	National Institute of Health - Intramural
National Institutes of Health	Postnatal Combination Therapy for Cerebral Palsy	\$333,795	Johns Hopkins University
National Institutes of Health	Rapid, In Vitro Phenotyping of Monogenic Neurological Disorders Using CRISPRi and High-Throughput All-Optical Electrophysiology.	\$550,626	Q-State Biosciences, Inc.
National Institutes of Health	Development of Roralpha and Rorgamma Ligands for Treatment of Behavioral Disorders	\$59,600	Saint Louis University
National Institutes of Health	Prefrontal Function in the Shank3-Deficient Rat: A First Rat Model for ASD	\$457,912	Icahn School of Medicine at Mount Sinai
National Institutes of Health	Chemicogenetic Rescue of Autism-Like Social Deficits in Shank3-Deficient Mice	\$79,750	State University of New York, Stony Brook

Funder	Project Title	Funding	Institution
National Institutes of Health	Developing a Prenatal Biologic Therapy to Mitigate ASD Risk from Maternal Autoantibodies to Caspr2	\$677,502	Spark2Flame, Inc.
National Institutes of Health	Discovery of Novel Drugs for Autism	\$382,982	Asddr, Llc
National Institutes of Health	Impact of Combined Medication and Behavioral Treatment in Young Children with Comorbid ASD and ADHD	\$475,076	Duke University
National Institutes of Health	Fatty Acid Supplements Alter Biological Signatures in Children with Autism Spectrum Disorder	\$260,967	Research Inst Nationwide Children'S Hosp
National Institutes of Health	PTP1B Inhibitors for the Treatment of Rett Syndrome	\$204,406	Case Western Reserve University
National Institutes of Health	Resveratrol-Mediated Regulation of Inflammatory Pathways in Autism Spectrum Disorders	\$219,750	University of South Carolina at Columbia
National Institutes of Health	Road to Discovery for Combination Probiotic BB-12 with LGG in Treating Autism Spectrum Disorder	\$425,155	University of Texas Hlth Sci Ctr Houston
Simons Foundation	Neural circuitry linking oxytocin deficiency and social impairment in ASD	\$75,000	University of California, Los Angeles
Simons Foundation	Expr. & character of neuron-specific potassium chloride cotransporter, KCC2	\$100,000	The Regents of the University of California, San Francisco (Contracts & Grants)
Simons Foundation	Randomized Controlled Pilot Trial of Pregnenolone in Autism	\$0	Stanford University
Simons Foundation	Detecting and Treating Social Impairments in a Monkey Model	\$164,588	Stanford University
Simons Foundation	Autism synaptic endophenotypes & candidate drug rescue	\$150,000	Stanford University
Simons Foundation	Development of CRISPRa therapeutics to rescue SCN2A function	\$80,000	The Regents of the University of California, San Francisco (Contracts & Grants)
Simons Foundation	Synthetic Infrared Nanosensors for Real-time Monitoring of Oxytocin Release	\$734	The Regents of the University of California, Berkeley
Simons Foundation	Translating Drug Discovery in Zebrafish and Mouse Models of ASD Risk Genes	\$123,833	Yale University
Simons Foundation	Translating Neuroprediction into Precision Medicine via Brain Priming - Core	\$0	Yale University
Simons Foundation	Modulation of mitochondrial efficiency to treat Fragile X Syndrome	\$146,077	Yale University
Simons Foundation	Translating Neuroprediction into Precision Medicine via Brain Priming - Project 1	\$0	The George Washington University
Simons Foundation	Structural biological studies of the cytoplasmic domain of KCC2	\$276,992	New York Structural Biology Center
Simons Foundation	Clinical Research Associates	\$1,660,000	Clinical Research Associates
Simons Foundation	Safety, Efficacy and Basis of Oxytocin and Brain Stimulation Therapy in ASD	\$0	University of Pennsylvania
Simons Foundation	Translating Neuroprediction into Precision Medicine via Brain Priming - Project 1	\$0	The Rector and Visitors of the University of Virginia

Funder	Project Title	Funding	Institution
Simons Foundation	Modulation of a splicing regulatory network commonly disrupted in autism	\$150,000	Governing Council of the University of Toronto
Simons Foundation	Restoring FMRP to reverse Fragile X Syndrome	\$79,800	The University of Calgary
Simons Foundation	Regulation of KCC2 as a target for treatment of Autism	\$75,000	University Laval
Simons Foundation	BKCa channels openers for the treatment of sensory hypersensitivity in ASD	\$230,498	Institut National de la Santé et de la Recherche Médicale-ADR-Bordeaux
Simons Foundation	Generating EEG biomarkers of treatment outcome	\$168,468	Birkbeck College
Agency for Healthcare Research and Quality	Ambulatory Pediatric Safety Learning Lab	\$560,539	Cincinnati Children's Hospital Medical Center
National Science Foundation	US Ignite: Focus Area 1: A Networked Virtual Reality Platform for Immersive Online Social Learning of Youth with Autism Spectrum Disorders	\$0	University of Missouri
The New England Center for Children	A behavioral analysis of anxiety in children with autism	\$5,800	The New England Center for Children
FRAXA Research Foundation (FRAXA)	Understanding and Reversing Hypersensitivity to Sounds in Fragile X Syndrome	\$90,000	University of California at Riverside School of Medicine
FRAXA Research Foundation (FRAXA)	Recruiting: Fragile X Clinical Trial of New PDE4D Inhibitor from Tetra	\$200,043	Tetra Discovery Partners & Rush University Medical Center
FRAXA Research Foundation (FRAXA)	Enhancing NMDA Receptor Signaling to Treat Fragile X Syndrome	\$45,000	Massachusetts Institute of Technology
FRAXA Research Foundation (FRAXA)	Pharmacological Tolerance in the Treatment of Fragile X Syndrome	\$90,000	Massachusetts Institute of Technology (MIT)
FRAXA Research Foundation (FRAXA)	Fragile X Clinical Trial of AZD7325 in Adults	\$0	Cincinnati Children's Hospital Medical Center
FRAXA Research Foundation (FRAXA)	A Kinase Assay as a Biomarker for Fragile X Syndrome	\$0	University of Antwerp
FRAXA Research Foundation (FRAXA)	Recruiting: Clinical Trial of Metformin for Fragile X Syndrome	\$50,000	University of Sherbrooke
FRAXA Research Foundation (FRAXA)	Reintroducing FMRP via Tat to Reduce Symptoms of Fragile X Syndrome	\$100,000	University of Calgary, Alberta
FRAXA Research Foundation (FRAXA)	Coffee, Tea, and Chocolate: Adenosine Receptors in Fragile X	\$90,000	Italian National Institute of Health
FRAXA Research Foundation (FRAXA)	Repurposing Study II: Evaluating Combinations of Drugs to Treat Fragile X	\$0	Healx

